Linda Yaccarino’s subsequent position after departing X as CEO will probably be one other chief govt position at eMed Inhabitants Well being, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting govt at NBCUniversal, however left to affix X as CEO for 2 years, the place she managed to have a constructive influence on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared method to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed mentioned in a press launch that they sought her out for her “plain skill to barter new partnerships” — it definitely additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed beforehand produced a tech platform that was designed for use with at-home COVID-19 fast antigen assessments, guiding customers via the method of administering these assessments correctly. Now, eMed is concentrated on GLP-1s, the category of medicine like Ozempic, which can be utilized for each weight administration and remedy of kind II diabetes.
“To be a frontrunner in in the present day’s healthcare market, corporations must have a fearless tenacity that permits them to not solely develop, however to even be courageous sufficient to step ahead and redefine a whole trade,” Yaccarino mentioned in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final purpose of enhancing world healthcare outcomes via our groundbreaking providers and platforms.”
